AADI
Aadi Bioscience, Inc. [AADI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AADI Stock Summary
Top 10 Correlated ETFs
AADI
Top 10 Correlated Stocks
AADI
In the News
AADI Financial details
Company Rating
-
Market Cap
48.13M
Income
-64.22M
Revenue
24.35M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
89
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.77
Forward P/E
-
PEG
1.3
P/S
1.87
P/B
0.4
P/C
-
P/FCF
-0.67
Quick Ratio
6.1
Current Ratio
6.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.38
EPS next Y
-
EPS next Q
-
EPS this Y
-3.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.27%
Revenue last 5Y
100.64%
Revenue Q/Q
6.16%
EPS Q/Q
-
-
-
-
-
SMA20
-11.11%
SMA50
13.81%
SMA100
43.92%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-45%
ROC
-0.58%
Gross Margin
91%
Oper. Margin
-300%
Profit Margin
-266%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.55-8.65
52W High
-65.13%
52W Low
+179%
RSI
48.56
Rel Volume
0.29
Avg Volume
374.81K
Volume
109.91K
Perf Week
3.33%
Perf Month
-25.2%
Perf Quarter
66.07%
Perf Half Y
80%
-
-
-
-
Beta
0.298
-
-
Volatility
0.11%, 0.24%
Prev Close
-2.45%
Price
2.79
Change
-3.79%
Company Profile
- Volume Average 374.81K
- Market Capitalization 48.13M
- Employee 89
- CEO Mr. David J. Lennon Ph.D.
- Headquarters Pacific Palisades,CA,US
- IPO Date 2018-02-16
-
Website
https://aadibio.com 
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
